Why Japan is largely a spectator in the coronavirus vaccine race
TOKYO >> Japan’s development of COVID-19 vaccines is far behind that of other countries, and the Japanese public is unlikely to have access to domestic vaccines until 2022.
Industry sources blame the situation on a failure to promote consolidation within the pharmaceutical industry and the sheltering of small Japanese companies from international competition.
The day the U.K. became the first western country to begin inoculating its citizens, biotech startup AnGes Inc. — Japan’s front-runner — announced it had started a mid- to late-stage clinical trial of its vaccine.
A total of 52 vaccine candidates were in clinical evaluation worldwide as of mid-November, according to the World Health Organization. The one under development by AnGes was the only Japanese contender. Other candidates from Japan are still in pre-clinical evaluation.
I hate to keep beating up on Japan, but it's just a cautionary tale of what can happen if a country loses its vitality. In today's globalized marketplace you need big champions, you can't rely on small mom-and-pop companies competing on price with an undifferentiated product to move up the value chain. You need large companies with the R&D budget to advance technological frontiers.
Similarly, you can't protect everything behind an isolationist, autarkic domestic market and expect that your companies will be able to compete with global companies that go head to head with the whole world.